7 results about "Nucleoside Analog Reverse Transcriptase Inhibitor" patented technology

The invention belongs to the technical field of medicines, and particularly relates to pyrrolo [2, 3-d] pyrimidine compounds of aryl fragments and piperidine fragments as well as a preparation method and application of the pyrrolo [2, 3-d] pyrimidine compounds. The pyrrolo [2, 3-d] pyrimidine compound containing the aryl fragment and the piperidine fragment is an HIV-1 reverse transcriptase inhibitor, and the pyrrolo [2, 3-d] pyrimidine compound further comprises pharmaceutical salt, hydrate and solvate of the pyrrolo [2, 3-d] pyrimidine compound, polycrystal or eutectic of the pyrrolo [2, 3-d] pyrimidine compound, and precursors and derivatives with the same biological functions of the pyrrolo [2, 3-d] pyrimidine compound. The invention also relates to a preparation method of the compound and application of a composition containing one or more of the compounds in related medicines for treating AIDS and the like. The result of an in-vitro cellular level anti-HIV-1 activity experiment shows that the micromolecule has relatively strong anti-HIV-1 biological activity, can remarkably inhibit virus replication in MT-4 cells infected by HIV-1 viruses, and has relatively low cytotoxicity.

Cell culture media comprising luteinizing hormone, follicle-stimulating hormone and at least one histone acetyltransferase inhibitor or reverse transcriptase inhibitor are provided. Methods of in vitro maturing a human oocyte, determining suitability for in vitro maturation, as well as kits comprising media, luteinizing hormone, follicle-stimulating hormone and at least one histone acetyltransferase inhibitor or reverse transcriptase inhibitor are also provided.

The present disclosure provides methods for treating HBV infection using combination therapies in patients with serum HBsAg levels below 3000 IU / mL prior to treatment. The components of the combination therapies may include one or more of an anti-HBV antibody; an siRNA that targets an HBV mRNA; interferon-α; and a nucleos(t)ide reverse transcriptase inhibitor (NRTI).

A combination comprising a tricycle compound and use thereof in the preparation of a medicament for treating HBV. The combination is a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof and any one drug in the following groups a-c: a. a hepatitis B surface antigen inhibitor, b. a reverse transcriptase inhibitor, and c. a hepatitis B surface antigen inhibitor and a reverse transcriptase inhibitor.

Disclosed is a method for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one reverse transcriptase inhibitor (RTI).

The present invention relates to an improved process for the preparation of (((1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methyl)(phenoxy)phosphoryloxy)methyl pivalate Compound (1) or its pharmaceutically acceptable salts thereof. The compound is useful as nucleotide reverse transcriptase inhibitor in therapy for diseases which respond to inhibition of protein kinase activity in humans in need thereof.

The invention relates to a carbonyl-substituted pyrimidine derivative as well as a preparation method and application thereof, and belongs to the technical field of organic compound synthesis and medical application. The carbonyl-substituted pyrimidine derivative has a structure as shown in a formula I. The carbonyl-substituted pyrimidine derivative disclosed by the invention is novel in structure and shows good anti-HIV-1 activity as an HIV-1 inhibitor, and the EC50 value of the carbonyl-substituted pyrimidine derivative ranges from 4.28 nM to 274 nM and is obviously superior to that of a drug nevirapine (EC50 = 281 + / -38.7 nM) on the market.